Melanoma Vaccine FDA-Cleared for Phase 3 Clinical Testing

Share this content:

(ChemotherapyAdvisor) – Melanoma patients may have received a shot of life today with news that a vaccine for the deadly cancer has received FDA clearance for Phase 3 clinical testing. Hong Kong-based CK Life Sciences made the exciting announcement today and its subsidiary Polynoma LLC, which developed the vaccine, will now be permitted to recruit patients for the trials. The news puts CK Life Sciences into a rare group of Asian pharmaceutical companies that have received clearance for the commencement of Phase 3 clinical testing of an investigational new drug.

Annually, new melanoma cases have reached upward of 132,000, worldwide, with 76,000 in the United States alone. With such a large number of new cases per year, and with limited treatment options currently available, the melanoma vaccine would be a welcome addition to the oncologists' treatment arsenal.

Polynoma's melanoma vaccine is polyvalent, HLA-unrestricted, and derived from partially purified tumor antigens extracted from three different proprietary melanoma cell lines. The vaccine is administered intravenously, along with the adjuvant, aluminum hydroxide.

Results from a double-blind, randomized, placebo-controlled, Phase 2 clinical trial demonstrated that the vaccine was efficacious in prolonging time to disease progression and overall survival in melanoma patients. The vaccine was also safe, with no grade 3 or grade 4 toxicity reported.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs